Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H25ClN2O4S |
| Molecular Weight | 448.963 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)[C@@H]2SC3=CC(Cl)=CC=C3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O
InChI
InChIKey=GYKFWCDBQAFCLJ-RTWAWAEBSA-N
InChI=1S/C22H25ClN2O4S/c1-14(26)29-20-21(15-5-8-17(28-4)9-6-15)30-19-13-16(23)7-10-18(19)25(22(20)27)12-11-24(2)3/h5-10,13,20-21H,11-12H2,1-4H3/t20-,21+/m1/s1
Clentiazem is a chloride derivative of diltiazem, originated in Tanabe Seiyaku. It works as a blocker of calcium channels. The drug was investigated in the clinical trials for the treatment of stable angina, and essential hypertension. Despite the positive results of clinical trials, no development of the drug was reported.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| 1,5-Benzothiazepine, a versatile pharmacophore: a review. | 2008-11 |
|
| Effects of first and second generation calcium channel blockers on diastolic function of the failing hamster heart: relationship with coronary flow changes. | 2003-07 |
|
| Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. | 2001-10 |
|
| Protective effect of clentiazem against epinephrine-induced cardiac injury in rats. | 1993-07 |
|
| Protective effects of the calcium antagonists diltiazem and TA3090 against hepatic injury due to hypoxia. | 1992-12-01 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
96125-53-0
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
CLENTIAZEM
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
SUB06653MIG
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
100000080214
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL165667
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
DTXSID901028074
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
40DK034DRC
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
m3616
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
6453
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
C056595
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
C81679
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY | |||
|
57026
Created by
admin on Mon Mar 31 18:22:27 GMT 2025 , Edited by admin on Mon Mar 31 18:22:27 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
